SAN DIEGO, July 23, 2016 /PRNewswire-USNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal and state securities laws by Emergent BioSolutions, Inc. (NYSE: EBS ) and certain of its officers and board members. Emergent BioSolutions is a specialty biopharmaceutical company that develops, manufactures and sells specialized products to healthcare providers and governments. Specifically, a class action has been commenced in the USDC for the District of Maryland, on behalf of purchasers of Emergent Biosolutions securities between January 11, 2016 and June 21, 2016. The complaint alleges that defendants issued materially false and misleading information regarding the Company's business and financial prospects, particularly in relation to potential contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax.